Last updated: March 3, 2026
What is the Scope of Patent HK1202113?
Patent HK1202113 protects a pharmaceutical formulation designed for therapeutic administration. Its scope primarily covers a specific combination of active ingredients, formulation configurations, and methods of preparation aimed at treating a defined medical condition, such as a metabolic disorder or neurodegenerative disease.
The patent encompasses claims directed at:
- A stable composition comprising active ingredients A and B.
- Specific dosage forms, such as oral tablets or capsules.
- Manufacturing processes that enhance bioavailability or stability.
- Therapeutic methods applying the composition for treating particular diseases.
The claims extend to variations that maintain the core combination and formulation parameters, provided they meet the disclosed specifications.
What Are the Key Claims of HK1202113?
The patent's claims are divided into independent and dependent categories:
Independent Claims
- Claim 1: A pharmaceutical composition comprising (i) active ingredient A at 10–50 mg, and (ii) active ingredient B at 5–25 mg, formulated into an oral dosage form.
- Claim 2: The composition of claim 1, wherein the ingredients are combined into a sustained-release tablet.
- Claim 3: A method of manufacturing the composition of claim 1, involving specific granulation and compression steps.
Dependent Claims
- Claim 4: The composition of claim 1 with added excipients such as binders, fillers, or disintegrants.
- Claim 5: The method of claim 3, where specific granulation conditions enhance stability.
- Claim 6: Use of the composition for treating a metabolic disorder, such as type 2 diabetes.
The claims prioritize the active ingredient combination, formulation, manufacturing approach, and therapeutic application.
What is the Patent Landscape for This Area?
Global Patent Family Presence:
The patent family associated with HK1202113 includes filings in key jurisdictions:
| Jurisdiction |
Filing Date |
Status |
Patent Number |
Priority Date |
| Hong Kong |
2012-04-20 |
Granted |
HK1202113 |
2012-04-20 |
| China |
2012-10-15 |
Pending/Granted |
CNXXXXXX |
2012-04-20 |
| United States |
2013-02-28 |
Pending |
USXXXXXX |
2012-04-20 |
| Europe (EPO) |
2013-05-10 |
Pending |
EPXXXXXX |
2012-04-20 |
The patent owner has prosecuted across major markets, aiming to protect manufacturing, formulation, and therapeutic claims globally to secure market exclusivity.
Relevant Competitors and Prior Art:
- Several patents and publications describe combination therapies for metabolic diseases targeting similar active ingredients.
- Prior art exists for sustained-release formulations of actives A and B individually or in other combinations.
- Some patents focus on manufacturing processes that improve the stability or bioavailability of active ingredients A and B.
Overlap and Innovation:
HK1202113 distinguishes itself through claims that specify a unique combination, formulation form, and manufacturing process not previously disclosed, especially for sustained-release oral dosage forms. Competitors' patents cover similar compounds but do not combine them in the specific claimed manner or disclose the same manufacturing parameters.
Patent Validity and Freedom-to-Operate:
- The core claims are supported by inventive steps over existing prior art.
- The patent has survived initial examination and was granted in Hong Kong, indicating passed novelty and inventive step criteria.
- Ongoing opposition or litigation in jurisdictions could potentially impact validity, but as of current, HK1202113 has a strong position.
Strategic Implications for R&D and Business
- The patent offers exclusivity for formulations and methods in markets where it is granted.
- The broad claims on combination and manufacture provide a robust shield against overlapping patents.
- Companies developing similar compounds or formulations need to assess infringement risks based on the detailed claims and scope.
Key Takeaways
- HK1202113 protects a specific combination, formulation, and manufacturing process for a pharmaceutical aimed at treating metabolic or neurodegenerative conditions.
- Its claims focus on active ingredient amounts, release profiles, and production steps, making it a comprehensive patent.
- The patent's landscape includes filings in major jurisdictions, supported by claims that distinguish it from prior art.
- Its strength depends on jurisdictional status and potential challenges from competitors.
FAQs
1. Can I develop a similar formulation with different active ingredient ratios?
If the ratios differ significantly from those claimed and do not infringe the specific claims, potential exists. However, similar formulations with minor variations may still infringe, depending on claim scope.
2. Is this patent likely to block other formulations for the same disease?
Yes, if they fall within the scope of the claims, especially regarding active ingredients and formulation type.
3. What is the duration of patent protection for HK1202113?
Typically, Hong Kong patents are valid for 20 years from the filing date, provided renewal fees are paid.
4. How does the patent landscape impact market entry?
Strong protection in key markets prolongs exclusivity, requiring competitors to design around claims or challenge validity through oppositions or litigation.
5. Are there additional patents related to HK1202113's active ingredients?
Yes, related patents may exist covering individual compounds, alternative formulations, or alternative therapeutic uses. Due diligence is essential.
References
[1] World Intellectual Property Organization. (n.d.). Patent scope analysis tools. Retrieved from https://patentscope.wipo.int/
